We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-21.22%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.48B
AUM Growth
-$2.59B
Cap. Flow
-$1.26B
Cap. Flow %
-13.32%
Top 10 Hldgs %
78.76%
Holding
139
New
5
Increased
29
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$300M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$200M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$81.4M
4
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$68.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$56.3M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$313M
2
GILD icon
Gilead Sciences
GILD
+$25.3M
3
MDVN
MEDIVATION, INC.
MDVN
+$12M
4
CPRX
Catalyst Pharmaceutical
CPRX
+$4.31M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$4.11M

Sector Composition

Rank Sector Weight
1 Healthcare 77.25%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OSIR
76
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$2.85M 0.03%
499,193
– –
EPZM
77
DELISTED
Epizyme, Inc
EPZM
$2.82M 0.03%
232,481
– –
NVIV
78
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
$2.79M 0.03%
+21
New +$2.25M
QURE icon
79
uniQure
QURE
$2.76B
$2.73M 0.03%
230,000
+200,000
+667% +$2.95M
ADMS
80
DELISTED
Adamas Pharmaceuticals
ADMS
$2.5M 0.03%
+172,630
New +$2.91M
VIRX
81
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.4M 0.03%
21,190
– –
IONS icon
82
Ionis Pharmaceuticals
IONS
$9.03B
$2.31M 0.02%
57,140
– –
TARA icon
83
Protara Therapeutics
TARA
$213M
$2.31M 0.02%
7,465
– –
ENTA icon
84
Enanta Pharmaceuticals
ENTA
$363M
$2.21M 0.02%
75,357
– –
AUPH icon
85
Aurinia Pharmaceuticals
AUPH
$1.92B
$2.08M 0.02%
711,499
– –
TRIL
86
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.96M 0.02%
211,792
– –
KPTI icon
87
Karyopharm Therapeutics
KPTI
$155M
$1.94M 0.02%
14,466
– –
IMDZ
88
DELISTED
Immune Design Corp.
IMDZ
$1.94M 0.02%
148,937
– –
IRWD icon
89
Ironwood Pharmaceuticals
IRWD
$593M
$1.85M 0.02%
201,981
– –
MDWD icon
90
MediWound
MDWD
$186M
$1.82M 0.02%
32,286
+143
+0.4% +$7.47K
CYTR
91
DELISTED
CytRx Corp
CYTR
$1.77M 0.02%
109,999
– –
STML
92
DELISTED
Stemline Therapeutics, Inc.
STML
$1.55M 0.02%
333,497
– –
ISEE
93
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.51M 0.02%
35,649
– –
AFMD
94
DELISTED
Affimed
AFMD
$1.5M 0.02%
40,000
– –
DVAX
95
DELISTED
Dynavax Technologies
DVAX
$1.44M 0.02%
75,000
– –
CLLS
96
Cellectis
CLLS
$287M
$1.38M 0.01%
50,000
– –
SRRA
97
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.35M 0.01%
5,000
– –
SVRA icon
98
Savara
SVRA
$1.08B
$1.31M 0.01%
68,535
– –
ASMB icon
99
Assembly Biosciences
ASMB
$494M
$1.25M 0.01%
20,833
– –
AMRN
100
Amarin Corp
AMRN
$300M
$1.23M 0.01%
40,093
-70,193
-64% -$2.08M
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2016 Portfolio in Review

As of Q1 2016, Baker Bros. Advisors held 139 positions worth $9.48B, down 21% from $12.1B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Baker Bros. Advisors withdrew a net $1.26B in Q1 2016, closing 5 positions and reducing 8 holdings. Its most notable exit was DYAX CORPORATION, an estimated $313M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 73% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in BeOne Medicines Ltd worth $56.1M.

  • Baker Bros. Advisors's largest Q1 2016 buy was BeOne Medicines Ltd: 1,912,680 shares worth $56.1M.
  • Baker Bros. Advisors added most to Incyte in Q1 2016, an estimated $300M increase.
  • Baker Bros. Advisors's biggest Q1 2016 reduction was MEDIVATION, INC., cutting an estimated $12M.
  • Baker Bros. Advisors fully exited DYAX CORPORATION in Q1 2016, selling an estimated $313M.
  • Baker Bros. Advisors's ten largest holdings make up 79% of its $9.48B portfolio in Q1 2016.
  • Baker Bros. Advisors opened 5 new positions and closed 5 in Q1 2016.
  • Baker Bros. Advisors's portfolio value fell 21% quarter-over-quarter to $9.48B.

Based on Baker Bros. Advisors's 13F filing for Q1 2016, filed 16 May 2016.